Press Releases

Date	Title	Company
16-Feb-2022	Two Million Euros for XO Life GmbH's Patient Insights Platform	B3C newswire
16-Feb-2022	European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older	Global Blood Therapeutics, Inc.
16-Feb-2022	atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine	atai Life Sciences
16-Feb-2022	Mechanical Properties of Biological Tissues Described the Easy Way	Karl Landsteiner University of Health Sciences
16-Feb-2022	New PROFINET-enabled pumps from Watson-Marlow enable seamless integration of fluid delivery up to enterprise-level	Sciad Newswire
16-Feb-2022	Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus	AstraZeneca
16-Feb-2022	Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus	AstraZeneca
16-Feb-2022	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults	Pfizer
16-Feb-2022	Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency	Pfizer
16-Feb-2022	Boyds boosts specialist clinical expertise with new hire	Boyds
16-Feb-2022	MODERNA ANNOUNCES PLAN TO EXPAND FOOTPRINT IN ASIA WITH FOUR ADDITIONAL SUBSIDIARIES	MODERNA
16-Feb-2022	Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform	Curve Therapeutics
16-Feb-2022	SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline	SpliceBio
16-Feb-2022	Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years	Moderna, Inc.
16-Feb-2022	Defence Therapeutics Inc.: DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER	Defence Therapeutics Inc.
16-Feb-2022	Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment	Relief Therapeutics Holding SA
15-Feb-2022	Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer	Intellia and ONK Therapeutics
15-Feb-2022	FIRST CPD STANDARDS FOR HEALTHCARE COMMUNICATIONS PROFESSIONALS	Healthcare Communications Association
15-Feb-2022	ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10	ProQR Therapeutics N.V.
15-Feb-2022	Immutep granted Australian patent for Eftilagimod Alpha, a soluble LAG-3 protein, in combination with a PD-1 pathway inhibitor	Immutep Limited